User:Mr. Ibrahem/Retifanlimab

Retifanlimab, sold under the brand name Zynyz, is a medication used to treat Merkel cell carcinoma. Specifically it is used for advanced disease. It is given by injection into a vein.

Common side effects include tiredness, muscle pain, itchiness, diarrhea, fever, and nausea. Other side effects may include immune mediated disorders including hepatitis, colitis, and pneumonitis and infusion reactions. Use in pregnancy may harm the baby. It is a monoclonal antibody which blocks programmed death receptor-1 (PD-1).

Retifanlimab was approved for medical use in the United States in 2023. As of 2023 in the United States it costs about 15,000 USD per dose.